[ad_1]
What you should know:
– Pear Therapeutics, Inc. (Nasdaq: PEAR), announced that it has acquired two new digital therapeutic assets that it intends to integrate into a prescription-only digital therapeutic potential (PDT) to treat patients through a continuum of subtypes and severity of depression.
– In addition, Pear announced yesterday the expansion of its existing initiative with Crossroads. With this expansion, Pear’s PDTs, reSET® and reSET-O®, have the potential to reach thousands of additional patients a month on their recovery trip to Kentucky, New Jersey, Pennsylvania and Virginia.
Pear Therapeutics, Inc. (Nasdaq: PEAR), a provider of software development and marketing of so-called prescription digital therapies (PDTs), announced the acquisition of two new digital therapeutic assets, from Waypoint Health Innovations, LLC, and a researcher named Fredrik Holländare from the University of Örebro, which are designed to treat a spectrum of depressive conditions. Pear intends to leverage these two new assets to expand its depression candidate product to treat mild, moderate, severe, and treatment-refractory depression.
Acquisition Optimize Your Prescription Digital Therapeutic Candidate
Pear’s candidate for depression is being developed for use alone or in combination with other treatments to help patients with a wide range of depressive symptoms. Pear intends to incorporate newly acquired and licensed assets into Pear’s candidate for depression, which will require a clinical evaluation and, if promising, will be evaluated in a potential fundamental clinical trial to support the FDA filing. .
Pear’s end-to-end platform discovers, develops and delivers PDT to patients. Pear’s platform is designed to be scalable with the ability to host multiple PDTs developed by Pear and potentially third parties. Pear’s development platform, PearCreate ™, aims to develop PDT candidates, and Pear’s trading platform, PearConnect, is focused on marketing PDT products.
Acquired digital therapeutic assets
The asset acquired by Waypoint Health Innovations is a digital therapy for depression based on structured and proven cognitive-behavioral therapy (CBT) techniques. The Waypoint Health asset emulates CBT through the use of standardized symptom assessments, videos, interactive tools, and algorithms that dynamically customize each individual’s experience.
The other asset is Fredrik Holländare from Örebro University. Its candidate for depression includes Internet-based CBT (iCBT) for the treatment of residual symptoms of depression and aims to prevent relapse. The treatment focuses on nine modules, which include an introduction to the CBT and depression module, two modules on behavioral activation, cognitive restructuring, sleep and relaxation, mindfulness, physical activity, anxiety reduction, and goal setting. long term.
Why it matters
The COVID-19 pandemic has greatly worsened depression in the United States over the past two years. A recent study by Brown University and Boston University found that in 2021, 32.8% of American adults experienced depressive symptoms compared to 27.8% of adults at the onset of the pandemic. and 8.5% before the pandemic.11 This rapid increase in depressive symptoms due to the pandemic. the pandemic highlights the growing need for new modes of treatment for depression.
“The addition of these depression assets to our portfolio fits perfectly with our short-term approach to expanding our leadership in psychiatry. With these offerings, we have the potential to optimize our PDT candidate for depression to help address one of the largest mental health and behavioral patient populations, ”said Corey McCann, president and CEO of Pear Therapeutics.
[ad_2]
Source link